VivoSeq
Gastroenterology

Paralytic Ileus

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Paralytic ileus is an early-stage landscape with 3 programs across 2 companies. The most active players are Takeda, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Unknown status1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus
Unknown status·PPrince of Songkla University·Phase 3·NCT04190173·62 enrolled
Effect of Preoperative Intrathecal Dexamethasone Versus Dexmedetomidine on Paralytic Ileus After Major Abdominal Surgery
Not yet recruiting·—·Phase 4·NCT06752317·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)